Sharps Technology Inc. Warrant

Healthcare US STSSW

0.0226USD
-0.0103(31.31%)

Last update at 2026-03-10T13:30:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.040.17
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap0.00000M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.79140M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.96

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2007-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2007-12-31
Income before tax -4.63966M -4.66441M -2.34029M -0.26300M -3.27916M
Minority interest - - - - -
Net income 0.78M -4.83116M -2.34716M -0.26300M -3.28630M
Selling general administrative 6.46M 2.81M 1.51M 0.00000M -
Selling and marketing expenses - - - - -
Gross profit - - - - 0.19M
Reconciled depreciation 0.65M 0.03M 0.00100M 0.00000M -
Ebit -8.73879M -4.49767M -2.33343M - -3.27916M
Ebitda -13.50377M -4.46897M -2.31219M 0.00000M -2.95614M
Depreciation and amortization -4.76497M 0.03M 0.02M - 0.32M
Non operating income net other - - - - -
Operating income -8.73879M -4.49767M -2.33343M 0.00000M -3.27916M
Other operating expenses 8.74M 4.50M 2.33M - 3.71M
Interest expense 1.32M 0.24M 0.26M 0.26M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income -1.32042M -0.16675M -0.23600M -0.26300M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.41955M 0.17M 0.00687M - 0.00714M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.34M
Total operating expenses 8.74M 4.50M 2.33M 0.00000M 3.57M
Cost of revenue - - - - 0.15M
Total other income expense net 4.10M -0.16675M -0.00687M - 0.10M
Discontinued operations - - - - -
Net income from continuing ops -4.63966M -4.66441M -0.56800M -0.26300M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 11.79M 11.84M 5.90M 2.23M 0.00000M
Intangible assets 0.00005M - - - -
Earning assets - - - - -
Other current assets 0.12M 0.07M 0.00800M 0.05M -
Total liab 3.85M 2.20M 2.77M 0.10M 2.02M
Total stockholder equity 7.93M 9.64M 3.14M 2.13M -2.01500M
Deferred long term liab - - - - -
Other current liab 2.90M 1.15M 2.07M -1.79775M 0.12M
Common stock 0.00153M 0.00094M 0.00052M 0.00046M 0.00900M
Capital stock 0.00153M 0.00094M 0.00052M 0.00046M -
Retained earnings -25.14900M -15.30737M -10.66770M -6.00329M -21.05500M
Other liab - - - - -
Good will 0.05M - - - -
Other assets 0.25M 0.48M - - -
Cash 3.01M 4.17M 1.48M 1.79M 0.00000M
Cash and equivalents - - - - -
Total current liabilities 3.69M 2.01M 2.77M 0.10M 2.02M
Current deferred revenue - - -0.80414M - -
Net debt -3.01291M -4.17090M -0.77915M -1.79020M 1.90M
Short term debt - - 0.70M 1.90M 1.90M
Short long term debt - - 0.70M 2.13M 1.90M
Short long term debt total - - 0.70M 1.90M 1.90M
Other stockholder equity 32.49M 24.73M 13.80M 8.13M 13.81M
Property plant equipment - - - - -
Total current assets 4.84M 4.42M 1.61M 1.84M 0.00000M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory 1.71M 0.19M 0.12M 0.00000M -
Accounts payable 0.79M 0.85M 0.80M 0.10M 0.00000M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.59M 0.21M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 0.01M 0.53M 0.07M -
Deferred long term asset charges - - - - -
Non current assets total 6.95M 7.42M 4.29M 0.39M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2007-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2007-12-31
Investments -3.11792M -2.34373M -3.30200M 0.00000M -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 12.24M 5.18M 3.42M 0.00000M -
Change to operating activities - - - - -
Net income -4.63966M -4.66441M -2.34029M -0.26300M -3.28630M
Change in cash 2.69M -0.31104M 1.15M 0.00000M -1.56201M
Begin period cash flow 1.48M 1.79M 0.64M 0.88M 2.44M
End period cash flow 4.17M 1.48M 1.79M 0.64M 0.88M
Total cash from operating activities -6.43316M -3.14774M -1.88310M 0.00000M -2.33910M
Issuance of capital stock 14.20M 3.38M 3.42M - -
Depreciation 0.65M 0.03M 0.01M 0.00000M 0.32M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.03411M -0.12199M 0.00000M - -
Change to account receivables - - - - -
Sale purchase of stock 0.06M - - - -
Other cashflows from financing activities -0.03111M 1.80M -0.38720M - 0.78M
Change to netincome - - - - -
Capital expenditures 0.75M 2.27M 0.31M 0.00000M 0.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.20922M 0.11M -0.04924M 0.00000M 0.06M
Stock based compensation 1.01M 1.20M 0.49M - -
Other non cash items -3.25145M 0.18M 0.01M 0.26M 0.57M
Free cash flow -7.18550M -5.41647M -2.19530M 0.00000M -2.40651M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
STSSW
Sharps Technology Inc. Warrant
-0.0103 31.31% 0.02 - - - -
ISRG
Intuitive Surgical Inc
-0.54 0.11% 485.31 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
-1.02 0.83% 121.48 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
- -% 243.04 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
-0.39 0.24% 163.49 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

Sharps Technology Inc. Warrant

105 Maxess Road, Melville, NY, United States, 11747

Key Executives

Name Title Year Born
Mr. Alan R. Blackman Co-Chairman, Chief Investment Officer, COO & Sec. 1949
Mr. Robert M. Hayes CEO & Director 1967
Mr. Andrew R. Crescenzo CPA Chief Financial Officer 1956
Mr. Barry B. Berler Chief Technical Officer & Inventor 1954
Dr. Steven Hertz M.D. Chief Medical Officer 1962
Mr. Robert M. Hayes CEO & Director 1968
Mr. Ben Scheu Senior Director of Sales NA
Mr. Adam S. Holdsworth Managing Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.